These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8592019)

  • 21. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma].
    Schmutzler RK; Kempe A; Kiechle M; Beckmann MW
    Dtsch Med Wochenschr; 1999 May; 124(18):563-6. PubMed ID: 10356583
    [No Abstract]   [Full Text] [Related]  

  • 22. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
    Riem L
    MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
    [No Abstract]   [Full Text] [Related]  

  • 23. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study.
    Lynch HT; Watson P; Conway TA; Lynch JF; Slominski-Caster SM; Narod SA; Feunteun J; Lenoir G
    Arch Intern Med; 1993 Sep; 153(17):1979-87. PubMed ID: 8357282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Counselling, genetic testing and prevention in women with hereditary breast- and ovarian cancer. Interdisciplinary recommendations of the consortium "Hereditary Breast- and Ovarian Cancer" of the German Cancer AiD].
    Schmutzler R; Schlegelberger B; Meindl A; Gerber WD; Kiechle M;
    Zentralbl Gynakol; 2003 Dec; 125(12):494-506. PubMed ID: 14755360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
    Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
    Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current status and perspectives for genetic consultation and prophylactic medical examination of risk groups with malignant neoplasms of the female reproductive system and breast].
    Akulenko LV; Gar'kavtseva RF; Zhordania KI; Samgina AA
    Tsitol Genet; 1992; 26(1):38-42. PubMed ID: 1621284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetics and the multidisciplinary breast center.
    Peters JA; Rubinstein WS
    Surg Oncol Clin N Am; 2000 Apr; 9(2):367-96. PubMed ID: 10757850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
    Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K
    Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Foreword.
    Ashley SW
    Curr Probl Surg; 2010 Oct; 47(10):742. PubMed ID: 20816138
    [No Abstract]   [Full Text] [Related]  

  • 33. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
    Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
    Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations.
    Khabele D; Runowicz CD
    Curr Womens Health Rep; 2002 Jun; 2(3):163-9. PubMed ID: 12099190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues in the genetic assessment of predispositions for familial breast and ovarian cancer.
    Mark HF; McGowan KD
    Cytobios; 1996; 87(351):229-35. PubMed ID: 9214724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In families of ovarian cancer patients, breast cancer in females and colorectal cancers in males are overrepresented].
    Weber W; Almendral AC; Buser M; Gencikova A; Gencik A; Ludwig H; Obrecht JP; Torhorst J; Müller H
    Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):460-2. PubMed ID: 3623049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scaring up patients.
    Ortolon K
    Tex Med; 2008 Aug; 104(8):43-6. PubMed ID: 19306543
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic counselling for familial breast and ovarian cancer in Ontario.
    Andermann A; Narod SA
    J Med Genet; 2002 Sep; 39(9):695-6. PubMed ID: 12205116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.